Session 5: Evaluation of the Benefits, Costs and Consequences of New Genomic Technologies: A Societal Perspective

Monday, 20 April, 2015 - 16:00 to 18:00


Larry Lynd
Larry Lynd
University of British Columbia

New developments in genomic technologies result in increased pressures on private and public payers to pay for more treatments and testing within a constrained budget. Evidence of the cost effectiveness of these new technologies is required, including consideration of downstream costs; however, these evaluations raise questions regarding reimbursement of companion tests for pharmaceuticals, the societal value/willingness to pay for new genomic technologies, and the value of population-based screening. Therefore, this session will explore the nuances of health technology assessment and economic evaluation of new genomic technologies and personalized medicine, including the incorporation of societal values into decisions about funding, reimbursement, and priority-setting.

Session Evaluation